Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy - updated results from an expanded access programme

被引：0
|
作者：
不详
机构：
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：171 / 171
页数：1
相关论文
共 50 条
  • [21] Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer
    Oakman, Catherine
    Moretti, Erica
    Santarpia, Libero
    Di Leo, Angelo
    FUTURE ONCOLOGY, 2011, 7 (02) : 173 - 186
  • [22] Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results
    Loibl, Sibylle
    Turner, Nicholas C.
    Ro, Jungsil
    Cristofanilli, Massimo
    Iwata, Hiroji
    Im, Seock-Ah
    Masuda, Norikazu
    Loi, Sherene
    Andre, Fabrice
    Harbeck, Nadia
    Verma, Sunil
    Folkerd, Elizabeth
    Theall, Kathy Puyana
    Hoffman, Justin
    Zhang, Ke
    Bartlett, Cynthia Huang
    Dowsett, Mitchell
    ONCOLOGIST, 2017, 22 (09): : 1028 - 1038
  • [23] Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series
    Luigi Di Lauro
    Patrizia Vici
    Maddalena Barba
    Laura Pizzuti
    Domenico Sergi
    Massimo Rinaldi
    Anna Di Benedetto
    Isabella Sperduti
    Abeer M. Shaaban
    Valerie Speirs
    Marcella Mottolese
    Ruggero De Maria
    Marcello Maugeri-Saccà
    Breast Cancer Research and Treatment, 2014, 148 : 73 - 80
  • [24] Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series
    Di Lauro, Luigi
    Vici, Patrizia
    Barba, Maddalena
    Pizzuti, Laura
    Sergi, Domenico
    Rinaldi, Massimo
    Di Benedetto, Anna
    Sperduti, Isabella
    Shaaban, Abeer M.
    Speirs, Valerie
    Mottolese, Marcella
    De Maria, Ruggero
    Maugeri-Sacca, Marcello
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 148 (01) : 73 - 80
  • [25] Lapatinib as salvage therapy in metastatic breast cancer: Preliminary results from an expanded access program
    Giotta, F.
    Latorre, A.
    Monticelli, G.
    Oliva, S.
    Albano, D.
    Colucci, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] Endocrine therapy for the treatment of postmenopausal women with breast cancer
    Harichand-Herdt, Seema
    Zelnak, Amelia
    O'Regan, Ruth
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (02) : 187 - 198
  • [27] ADHERENCE TO ENDOCRINE THERAPY IN POSTMENOPAUSAL WOMEN WITH BREAST CANCER
    Bauer, T.
    Ziller, M.
    Holzhauer, W.
    Ziller, V.
    Wagner, U.
    Hadji, P.
    ANTICANCER RESEARCH, 2008, 28 (6B) : 4063 - 4063
  • [28] Fulvestrant (Faslodex) in women with metastatic breast cancer after progression on prior anti-estrogenic therapy
    Di Bitonto, Pasqualina
    Abate, Antonio
    Vessia, Giacomo
    De Lena, Mario
    ANNALS OF ONCOLOGY, 2007, 18 : 49 - 49
  • [29] Fulvestrant in pretreated postmenopausal patients with metastatic breast cancer: analysis from the French multicentre compassionate use programme
    Gligorov, J.
    Antoine, E. C.
    Dalenc, F.
    Namer, M.
    Chollet, P.
    Spielmann, M.
    Campone, M.
    Zelek, L.
    Debled, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S116 - S116
  • [30] ECONOMIC EVALUATION AND BUDGET IMPACT OF FULVESTRANT (FASLODEX®) IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE NOT RECEIVED PRIOR ENDOCRINE THERAPY FROM THE PERSPECTIVE OF THE PUBLIC HEALTHCARE SYSTEM IN MEXICO
    Carlos, F.
    Guzman, J.
    Naranjo, M.
    Carmona, M.
    VALUE IN HEALTH, 2019, 22 : S81 - S81
12345